Bispecific Factor VIII mimetic antibody
By developing a bispecific antibody that can bind to FIX(a) and FX(a), the risk of inhibitor formation and the inconvenience of injection in factor VIII replacement therapy for hemophilia A patients have been resolved, achieving more efficient coagulation function recovery and treatment convenience.
Patent Information
- Application Number
- CN202180011448.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-30
- Filing Date
- 2021-01-29
- Publication Date
- 2025-09-16
- Estimated Expiration
- 2041-01-29
AI Technical Summary
Existing coagulation factor VIII replacement therapy has the risk of inhibitor formation in patients with hemophilia A, resulting in poor treatment effect. In addition, conventional intravenous injection is inconvenient and cannot effectively restore coagulation function.
Develop a bispecific antibody that can bind to FIX(a) and FX(a), enhance the enzymatic activity of FIXa on FX, mimic the FVIII cofactor function, and be used to replace FVIII. The antibody includes human or humanized antibodies and antigen-binding fragments thereof, reduces nonspecific binding tendency and self-association, and is suitable for subcutaneous injection.
It improves the recovery of coagulation function in patients with hemophilia A, reduces the problem of shortened circulation half-life caused by nonspecific binding, and provides a more convenient and effective treatment plan.